Peter Kernen

Peter Kernen is a seasoned professional in the field of Life Sciences, currently serving as Sr. Director of Reagent & Clinical Operations at Fluxus Inc. since 2017, where responsibilities include assay development and preclinical research utilizing an optofluidic-based single-molecule detection platform. Kernen has diversified experience as an Independent Consultant since 2014, collaborating with companies like Nanomix Inc. and Quantapore Inc. Prior roles include Principal Scientist at Arbor Vita Corporation, Program Manager at Centofanti Consulting, and five years at Zyomyx, where contributions involved bioassay development and clinical research. Kernen's earlier career features significant positions at the Swiss Federal Laboratories and the Swiss Federal Institute of Technology, with a foundational research background originating from postdoctoral studies at the University of Geneva. Kernen attained a Ph.D. from the Theodor Kocher Institute, University of Bern, focusing on cytokine-induced signal transduction pathways.